25 March 2019 | News
Sosei Heptares announces that Ultibro® Breezhaler® and Seebri® Breezhaler® launched in China for the treatment of COPD
image credit- netdoctor.co.uk
Sosei Group Corporation confirms that Ultibro® Breezhaler® and Seebri® Breezhaler® have been launched by Novartis in China for the treatment of chronic obstructive pulmonary disease (COPD). The Company, together with Vectura, exclusively licensed key intellectual property integral to the development of both products to Novartis in April 2005 and is eligible for royalties on global product sales.
Ultibro® Breezhaler® is an inhaled once-daily fixed-dose combination of indacaterol (a long-acting beta 2 agonist; LABA) and glycopyrronium bromide (a long-acting muscarinic antagonist; LAMA) and Seebri® Breezhaler® is an inhaled fixed-dose formulation of glycopyrronium bromide (a long-acting muscarinic antagonist; LAMA). Both products are approved and launched in over 90 countries worldwide, including the US, EU and Japan.
Both products will be promoted in China by Huizheng (Shanghai) Technology Co., Ltd. (Huizheng), a group company of Zheijiang Hisun Pharmaceutical Co., Ltd. under license from Beijing Novartis Pharma Co., Ltd and Sandoz (China) Pharmaceutical Co., Ltd, both controlled subsidiaries of Novartis.
Huizheng has applied to include Ultibro® Breezhaler® and Seebri® Breezhaler® in the National Health Insurance Drug List.